Overview
Lobbying Costs
75,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.5 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Vifor Pharma Management
EU Transparency Register
723747633409-36 First registered on 06 Dec 2018
Goals / Remit
Vifor Pharma Group, formerly Galenica Group, is a global pharmaceutical company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions. The company’s goal is to be a global leader in iron deficiency, nephrology and cardio-renal therapies and strives to help patients around the world with severe and chronic diseases to lead better, healthier lives. Vifor Pharma Group has production sites in Switzerland and Portugal as well as a dynamic network of affiliates and partners offering broad market coverage all over the world.
Main EU files targeted
Healthcare policy, Chronic diseases, rare disease policy, Health Technology Assessment, pharmaceutical incentives assessment
Address
Head Office
Vifor Pharma
Flughofstrasse 61
Glattbrugg CH-8152
SWITZERLAND -
People
Total lobbyists declared
2
Employment time Lobbyists 25% 2 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Mr Emanuele Degortes (Head of Patient, Innovation and Access Policy)
Person with legal responsibility
Mr Walde Andreas (General Secretary)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
EFPIA
EUCOPEMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
75,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
None
Other activities
None declared
- Meetings
Meetings
None declared
- Meetings